IGHV3OR16-9

Across TCGA pan-cancer cohorts, IGHV3OR16-9 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IGHV3OR16-9 data layer compared with 20 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher IGHV3OR16-9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGHV3OR16-9 expression acts as an unfavorable survival marker.

KICH and LUSC are the cancer types where IGHV3OR16-9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
LUSC	OS	Median	II,III,IV	0.172	0.743	.003	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

IGHV3OR16-9–KICH (DFS)

Open the KICH breakdown →